# What to ask about a cartilage scan *Joint Regeneration Phoenix | What a Cartilage Scan Can Tell You* > Joint regeneration Phoenix answers what a scan may show, why soreness can differ from the image and what to ask after you get the report. ## What does my joint scan really mean? A scan may show worn cartilage, worn bone or swelling inside the joint. It can't measure how sore you feel. The worn area matters when it matches both your ache and the exam. A report can sound worse than the joint feels, or the reverse. That's why the doctor asks about walking, sleep, stairs and motion. I'd carry both the report and scan pictures to your visit. ## What to compare with the scan report Show the doctor precisely where you feel soreness. Explain which motion starts it and how long the ache stays. If the report names several worn areas, ask which one fits. Some worn areas may not be causing trouble now. Ask whether the scan shows one damaged area or wear across the joint. That difference can affect whether a repair operation makes sense. The exam keeps the scan from getting more weight than your daily symptoms. ## How to avoid an unneeded scan Ask what another scan would tell the doctor. If the result won't affect your care, the scan could add cost without helping. Find out whether your old scan is recent enough for this visit. Bring the written report so it isn't missed. If someone says cartilage grew, ask how its thickness or amount was measured. Then ask whether the person moved better or hurt less. Thicker cartilage on a scan isn't the same as relief. You'll need both answers before believing the claim. ## What to do when the report does not explain the soreness Don't assume the soreness is imagined because a scan shows little wear. The exam may point to a tendon, a tough cord between a muscle and bone. Your doctor can also check whether pain is coming from your back. A joint scan can't settle those questions alone. Ask what simple care fits the exam and how long to try it. If you aren't improving, arrange a follow-up instead of repeating the same care. Bring notes on whether soreness, swelling or motion improved between visits. ## Sources 1. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative. Bennell KL, et al. — [Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/34812863/). *JAMA*, 2021. DOI: 10.1001/jama.2021.19415. 2. A four-arm, multicentre, single-blind phase 2/3 randomized trial of 480 knee OA patients (KL II-IV) compared autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic umbilical-cord-tissue mesenchymal stromal cells against a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another, or to the corticosteroid control, and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events occurred. Mautner K, et al. — [Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.](https://pubmed.ncbi.nlm.nih.gov/37919438/). *Nature medicine*, 2023. DOI: 10.1038/s41591-023-02632-w. 3. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit. Awad G, et al. — [Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.](https://pubmed.ncbi.nlm.nih.gov/41863718/). *Clinical rheumatology*, 2026. DOI: 10.1007/s10067-026-08042-w. 4. FORWARD, the longest disease-modifying osteoarthritis drug trial reported to date, gave intra-articular sprifermin (a recombinant FGF-18) or placebo to knee OA patients and followed 378 of them for 5 years. Sprifermin produced a significant, sustained dose-response INCREASE in total femorotibial cartilage thickness versus placebo - and WOMAC pain improved about 50% from baseline in ALL groups, including placebo. It is the cleanest demonstration in the literature that adding measurable cartilage and relieving pain are two different results, and that one does not deliver the other. Eckstein F, et al. — [Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.](https://pubmed.ncbi.nlm.nih.gov/33962962/). *Annals of the rheumatic diseases*, 2021. DOI: 10.1136/annrheumdis-2020-219181. 5. A GRADE-rated systematic review and meta-analysis of 16 randomized trials (807 participants) found that MSC therapy for chronic knee OA pain PROBABLY RESULTS IN LITTLE TO NO DIFFERENCE in pain relief at 3-6 months (WMD -0.74 cm on a 10 cm VAS against a minimally important difference of 1.5 cm) or physical functioning (WMD 2.23 on the SF-36 100-point subscale against a 10-point MID), both moderate certainty; at 12 months pain was again probably little-to-no-different (WMD -0.73 cm). The measured effect is real but sits BELOW the threshold at which a patient would notice it. Sadeghirad B, et al. — [Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials.](https://pubmed.ncbi.nlm.nih.gov/38777213/). *Osteoarthritis and cartilage*, 2024. DOI: 10.1016/j.joca.2024.04.021. ## What to ask if it does not settle QC Kinetix offers regenerative treatments, a name for non-surgical care made from your own blood. PRP means blood that's spun to gather more platelets. Concentrated PRP is prepared to gather an even higher amount of platelets. Medical providers, meaning the trained people giving your care, prepare and provide it in a clinic for soreness due to a joint condition. These treatments aren't a promise that worn cartilage will grow back. Your first talk covers the sore joint, earlier care and the activity you miss most. Ask about the likely visit count, full cost and work needed afterward. Then you'll be able to decide without being rushed. Schedule a free consultation: --- Plain help for soreness, care at home and a useful visit. Joint regeneration Phoenix: why your joint may ache, ways to ease it yourself and when a visit makes sense. Simple guidance on aching joints, care at home, urgent signs and useful visit questions. This site is run by the Phoenix-area clinic owners of QC Kinetix. The business benefits when readers book, so the relationship is stated plainly and the signed research sources remain visible for checking. Copyright 2026 Phoenix Joint Field Guide. General health education only; a clinician who can examine the joint should guide personal medical decisions.